Medications For Heart Failure Global Market Report 2025
상품코드:1760629
리서치사:The Business Research Company
발행일:On Demand Report
페이지 정보:영문 175 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
심부전 치료제 시장 규모는 향후 몇 년 동안 강력한 성장을 보일 것으로 예상됩니다. 예측 기간 동안의 성장은 개인 맞춤형 의학 및 정밀 의학의 확대, 전 세계적으로 증가하는 생활 습관병의 부담, 강력한 복합 요법 및 고정 용량 제제의 파이프라인, 임상 증거 및 지침의 업데이트, 그리고 도시화의 진행과 같은 요인에 기인할 수 있습니다. 예측 기간의 주요 동향으로는 SGLT2 억제제의 성장, 디지털 건강 기술의 통합, 원격 모니터링 도구 및 AI 기반 분석의 사용, HFpEF 치료에 대한 관심 증가, 지속적인 연구 개발 노력 등이 있습니다.
심혈관 질환의 유병률이 증가함에 따라 향후 몇 년 동안 심부전 치료제 시장이 확대될 것으로 예상됩니다. 심혈관 질환은 심장과 혈관을 침범하는 질환으로, 심근경색과 뇌졸중과 같은 심각한 문제를 초래할 수 있습니다. 이 질환의 증가세는 주로 앉아서 생활하는 습관으로 인해 심장과 혈관 건강이 점차 악화되기 때문입니다. 이러한 질환의 발생률이 증가함에 따라 효과적인 치료법 수요도 증가하며, 이는 심부전 치료제 개발에 대한 투자를 촉진하고 있습니다. 질환의 유병률이 높아짐에 따라 제약 기업들은 증상 관리와 환자 예후 개선을 위해 치료법 개발 및 개선에 집중하고 있습니다. 예를 들어, 2024년 9월 미국 심부전 학회(HFSA)는 20세 이상 미국인 중 약 670만 명이 심부전(HF)을 앓고 있으며, 이 숫자는 2030년까지 870만 명, 2040년까지 1,030만 명, 2050년까지 1,140만 명으로 증가할 것으로 예상된다고 보고했습니다. 따라서 심혈관 질환의 발생률 증가가 심부전 치료제 시장의 성장에 주요 촉진요인으로 작용하고 있습니다.
심부전 치료제 시장 선도 기업들은 심부전 증상 및 합병증의 장기적 관리를 더 효과적으로 지원하는 나트륨-글루코스 공동수송체(SGLT) 억제제와 같은 고급 약물 개발에 집중하고 있습니다. SGLT 억제제는 포도당 재흡수 메커니즘을 표적으로 삼는 고급 약물로, 심부전 관리, 치료 효율성 향상, 심혈관 건강 최적화에 도움을 줍니다. 예를 들어, 2023년 5월 미국 바이오제약 기업인 Lexicon Pharmaceuticals는 식품의약국(FDA) 승인을 받은 약물 Inpefa(sotagliflozin)를 출시했습니다. Inpefa는 심부전 또는 제2형 당뇨병, 만성 신장 질환 및 기타 심혈관 위험 요인이 있는 성인의 심혈관 사망, 심부전으로 인한 입원 및 긴급 심부전 방문의 위험을 줄이기 위해 설계된 1일 1회 경구용 정제입니다. Inpefa는 시판된 최초의 이중 SGLT1/SGLT2 억제제로, 다양한 질환을 가진 심부전 환자에게 새로운 치료 옵션을 제공하기 때문에 이번 승인은 Lexicon에게 중요한 성과입니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향과 전략
제4장 시장 - 금리, 인플레이션, 지정학, 무역전쟁과 관세, 코로나 19 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
세계의 심부전 치료제 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
최종 이용 산업의 분석
세계의 심부전 치료제 시장 : 성장률 분석
세계의 심부전 치료제 시장 실적 : 규모와 성장(2019-2024년)
세계의 심부전 치료제 시장 예측 : 규모와 성장(2024-2029년, 2034년)
세계의 심부전 치료제 총 시장 규모(TAM)
제6장 시장 세분화
세계의 심부전 치료제 시장 : 약제 클래스별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
안지오텐신 전환효소(ACE) 억제제
베타 차단제
이뇨제
알도스테론 길항제
안지오텐신 II 수용체 길항제(ARB)
기타
세계의 심부전 치료제 시장 : 투여 경로별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
경구
정맥내
기타
세계의 심부전 치료제 시장 : 유통 채널별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
병원 약국
소매 약국
온라인 약국
기타
세계의 심부전 치료제 시장 : 용도별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
병원
클리닉
기타
세계의 심부전 치료제 시장 : 안지오텐신 전환 효소(ACE) 억제제 유형별 세분화, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
에나라프릴
리시노프릴
라미프릴
캡토프릴
페린드 프릴
기타
세계의 심부전 치료제 시장 : 베타 차단제 유형별 세분화, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
카르베지롤
메토프롤롤 숙신산염
비소프롤롤
네비보롤
기타
세계의 심부전 치료제 시장 : 이뇨제 유형별 세분화, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
루프 이뇨제
티아지드계 이뇨제
칼륨 유지성 이뇨제
기타
세계의 심부전 치료제 시장 : 알도스테론 길항제 유형별 세분화, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
스피로노락톤
에플레레논
기타
세계의 심부전 치료제 시장 : 안지오텐신 II 수용체 길항제(ARB) 유형별 세분화, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
발사르탄
로사르탄
칸데사르탄
일베사르탄
기타
세계의 심부전 치료제 시장 : 기타 약제 클래스 유형별 세분화, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
안지오텐신 수용체 네프릴라이신 억제제
이바브라진
나트륨-글루코스 공동수송체(SGLT) 억제제
히드라라진/질산이소소르비드
디곡신
기타
제7장 지역별, 국가별 분석
세계의 심부전 치료제 시장 : 지역별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
세계의 심부전 치료제 시장 : 국가별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 프로파일
심부전 치료제 시장 : 경쟁 구도
심부전 치료제 시장 : 기업 프로파일
Merck & Co. Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
Bayer AG : 개요, 제품 및 서비스, 전략 및 재무 분석
Sanofi SA : 개요, 제품 및 서비스, 전략 및 재무 분석
Bristol-Myers Squibb : 개요, 제품 및 서비스, 전략 및 재무 분석
AstraZeneca plc : 개요, 제품 및 서비스, 전략 및 재무 분석
제31장 기타 주요 기업 및 혁신 기업
Novartis AG
Eli Lilly and Company
Boehringer Ingelheim Pharmaceuticals Inc.
Steris Pharma
CSPC Pharmaceutical
Hikma Pharmaceuticals PLC
Cadila Pharmaceuticals
Ionis Pharmaceuticals Inc.
Valeant Pharmaceuticals International Inc.
Hainan Poly Pharm. Co. Ltd.
Addii Biotech
Lunan Pharmaceutical Group
Mylan Laboratories Inc.
Neuracle Lifesciences Private Limited
JM Laboratories
제32장 세계 시장 경쟁 벤치마킹과 대시보드
제33장 주요 인수합병(M&A)
제34장 최근 시장 동향
제35장 시장의 잠재력이 높은 국가, 부문, 전략
심부전 치료제 시장(2029년) : 새로운 기회를 제공하는 국가
심부전 치료제 시장(2029년) : 새로운 기회를 제공하는 부문
심부전 치료제 시장(2029년) : 성장 전략
시장 동향에 기초한 전략
경쟁 전략
제36장 부록
HBR
영문 목차
영문목차
Medications for heart failure are drugs designed to treat and manage heart failure, a condition in which the heart struggles to pump blood effectively to meet the body's needs. These medications help improve heart function, alleviate symptoms, prevent hospitalizations, and enhance survival.
The main drug classes used to treat heart failure include angiotensin-converting enzyme (ACE) inhibitors, beta-blockers, diuretics, aldosterone antagonists, angiotensin II receptor blockers (ARBs), and others. ACE inhibitors work by relaxing blood vessels through the inhibition of angiotensin II formation, which helps lower blood pressure and reduce the heart's workload. They are commonly prescribed for both high blood pressure and heart failure. These medications are administered via different routes, such as oral and intravenous, and are distributed through various channels, including hospital pharmacies, retail pharmacies, online pharmacies, and others. They are used in a range of settings, including hospitals, clinics, and more.
The medications for heart failure market research report is one of a series of new reports from The Business Research Company that provides medications for heart failure market statistics, including the medications for heart failure industry global market size, regional shares, competitors with the medications for heart failure market share, detailed medications for heart failure market segments, market trends, and opportunities, and any further data you may need to thrive in the medications for heart failure industry. This medications for heart failure market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The medications for the heart failure market size has grown strongly in recent years. It will grow from$10.14 billion in 2024 to $10.90 billion in 2025 at a compound annual growth rate (CAGR) of 7.4%. The growth during the historic period can be attributed to factors such as the rising prevalence of cardiovascular diseases, increased diagnosis and awareness, regulatory approvals and support, higher R&D spending on cardiovascular drugs, and the adoption of telemedicine and remote monitoring tools.
The medications for the heart failure market size is expected to see strong growth in the next few years. It will grow to$14.37 billion in 2029 at a compound annual growth rate (CAGR) of 7.2%. The growth during the forecast period can be attributed to factors such as the expansion of personalized and precision medicine, the rising global burden of lifestyle diseases, a robust pipeline of combination therapies and fixed-dose formulations, increasing clinical evidence and updated guidelines, and growing urbanization. Key trends in the forecast period include the growth of SGLT2 inhibitors, integration of digital health technologies, the use of remote monitoring tools and AI-driven analytics, a greater focus on HFpEF treatment, and ongoing research and development efforts.
The growing prevalence of cardiovascular diseases is expected to drive the expansion of the heart failure medications market in the coming years. Cardiovascular diseases encompass conditions affecting the heart and blood vessels, often leading to serious problems such as heart attacks and strokes. This rise in cardiovascular diseases is primarily due to sedentary lifestyles, which progressively impair heart and vessel health. As the incidence of these diseases increases, the demand for effective treatments also grows, prompting more investment in heart failure medications. With the condition becoming more common, pharmaceutical companies are focusing on developing and improving therapies to better manage symptoms and enhance patient outcomes. For example, in September 2024, the Heart Failure Society of America (HFSA) reported that approximately 6.7 million Americans aged 20 and older are living with heart failure (HF), a number expected to grow to 8.7 million by 2030, 10.3 million by 2040, and 11.4 million by 2050. Thus, the rising incidence of cardiovascular diseases is a key driver of the heart failure medications market's growth.
Leading companies in the heart failure medication market are focused on developing advanced drugs such as sodium-glucose cotransporter (SGLT) inhibitors, which offer more effective long-term management of heart failure symptoms and complications. An SGLT inhibitor is an advanced drug that targets glucose reabsorption mechanisms, helping to manage heart failure, enhance treatment efficiency, and optimize cardiovascular health. For example, in May 2023, Lexicon Pharmaceuticals, a US-based biopharmaceutical company, launched Inpefa (sotagliflozin), a medication approved by the Food and Drug Administration (FDA). Inpefa is a once-daily oral tablet designed to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visits in adults with heart failure or type 2 diabetes mellitus, chronic kidney disease, and other cardiovascular risk factors. This approval represents a significant achievement for Lexicon, as Inpefa is the first dual SGLT1/SGLT2 inhibitor to be marketed, offering a new treatment option for heart failure patients with various conditions.
In March 2024, Novo Nordisk, a Denmark-based pharmaceutical company, acquired Cardior Pharmaceuticals for $1.112 billion. The acquisition aims to strengthen Novo Nordisk's cardiovascular drug pipeline, particularly with Cardior's lead compound CDR132L, which is currently in phase 2 clinical trials for treating heart failure. Cardior Pharmaceuticals, based in Germany, specializes in researching oligonucleotide-based inhibitors for heart failure treatment.
Major players in the medications for heart failure market are Merck & Co. Inc., Bayer AG, Sanofi SA, Bristol-Myers Squibb, AstraZeneca plc, Novartis AG, Eli Lilly and Company, Boehringer Ingelheim Pharmaceuticals Inc., Steris Pharma, CSPC Pharmaceutical, Hikma Pharmaceuticals PLC, Cadila Pharmaceuticals, Ionis Pharmaceuticals Inc., Valeant Pharmaceuticals International Inc., Hainan Poly Pharm. Co. Ltd., Addii Biotech, Lunan Pharmaceutical Group, Mylan Laboratories Inc., Neuracle Lifesciences Private Limited, JM Laboratories, and Lexicon Pharmaceuticals.
North America was the largest region in the medications for the heart failure market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in medications for the heart failure report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the medications for the heart failure market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The medications for the heart failure market consist of sales of angiotensin receptor-neprilysin inhibitors, hydralazine and nitrates, ivabradine, and digoxin. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Medications For Heart Failure Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on medications for heart failure market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for medications for heart failure ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The medications for heart failure market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:1) By Drug Class: Angiotensin-Converting Enzyme (ACE) Inhibitors; Beta Blockers; Diuretics; Aldosterone Antagonists; Angiotensin II Receptor Blockers (ARBs); Other Drug Classes
2) By Route Of Administration: Oral; Intravenous; Other Routes Of Administration
3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies; Other Distribution Channels
4) By Application: Hospital; Clinic; Other Applications
Subsegments:
1) By Angiotensin-Converting Enzyme (ACE) Inhibitors: Enalapril; Lisinopril; Ramipril; Captopril; Perindopril; Other Angiotensin-Converting Enzyme (ACE) Inhibitors
2) By Beta Blockers: Carvedilol; Metoprolol Succinate; Bisoprolol; Nebivolol; Other Beta Blockers
3) By Diuretics: Loop Diuretics; Thiazide Diuretics; Potassium-Sparing Diuretics; Other Diuretics
4) By Aldosterone Antagonists: Spironolactone; Eplerenone; Other Aldosterone Antagonists
5) By Angiotensin II Receptor Blockers (ARBs): Valsartan; Losartan; Candesartan; Irbesartan; Other Angiotensin II Receptor Blockers (ARBs)
6) By Other Drug Classes: Angiotensin Receptor-Neprilysin Inhibitors; Ivabradine; Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors; Hydralazine Or Isosorbide Dinitrate; Digoxin; Other Medications
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Medications For Heart Failure Market Characteristics
3. Medications For Heart Failure Market Trends And Strategies
4. Medications For Heart Failure Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
5. Global Medications For Heart Failure Growth Analysis And Strategic Analysis Framework
5.1. Global Medications For Heart Failure PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Medications For Heart Failure Market Growth Rate Analysis
5.4. Global Medications For Heart Failure Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Medications For Heart Failure Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Medications For Heart Failure Total Addressable Market (TAM)
6. Medications For Heart Failure Market Segmentation
6.1. Global Medications For Heart Failure Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Angiotensin-Converting Enzyme (ACE) Inhibitors
Beta Blockers
Diuretics
Aldosterone Antagonists
Angiotensin II Receptor Blockers (Arbs)
Other Drug Classes
6.2. Global Medications For Heart Failure Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Oral
Intravenous
Other Routes Of Administration
6.3. Global Medications For Heart Failure Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Other Distribution Channels
6.4. Global Medications For Heart Failure Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospital
Clinic
Other Applications
6.5. Global Medications For Heart Failure Market, Sub-Segmentation Of Angiotensin-Converting Enzyme (ACE) Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Enalapril
Lisinopril
Ramipril
Captopril
Perindopril
Other Angiotensin-Converting Enzyme (ACE) Inhibitors
6.6. Global Medications For Heart Failure Market, Sub-Segmentation Of Beta Blockers, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Carvedilol
Metoprolol Succinate
Bisoprolol
Nebivolol
Other Beta Blockers
6.7. Global Medications For Heart Failure Market, Sub-Segmentation Of Diuretics, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Loop Diuretics
Thiazide Diuretics
Potassium-Sparing Diuretics
Other Diuretics
6.8. Global Medications For Heart Failure Market, Sub-Segmentation Of Aldosterone Antagonists, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Spironolactone
Eplerenone
Other Aldosterone Antagonists
6.9. Global Medications For Heart Failure Market, Sub-Segmentation Of Angiotensin II Receptor Blockers (ARBs), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Valsartan
Losartan
Candesartan
Irbesartan
Other Angiotensin II Receptor Blockers (ARBs)
6.10. Global Medications For Heart Failure Market, Sub-Segmentation Of Other Drug Classes, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Angiotensin Receptor-Neprilysin Inhibitors
Ivabradine
Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors
Hydralazine Or Isosorbide Dinitrate
Digoxin
Other Medications
7. Medications For Heart Failure Market Regional And Country Analysis
7.1. Global Medications For Heart Failure Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Medications For Heart Failure Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8. Asia-Pacific Medications For Heart Failure Market
8.1. Asia-Pacific Medications For Heart Failure Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Medications For Heart Failure Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Medications For Heart Failure Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Medications For Heart Failure Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Medications For Heart Failure Market
9.1. China Medications For Heart Failure Market Overview
9.2. China Medications For Heart Failure Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Medications For Heart Failure Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Medications For Heart Failure Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Medications For Heart Failure Market
10.1. India Medications For Heart Failure Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Medications For Heart Failure Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Medications For Heart Failure Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Medications For Heart Failure Market
11.1. Japan Medications For Heart Failure Market Overview
11.2. Japan Medications For Heart Failure Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Medications For Heart Failure Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Medications For Heart Failure Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Medications For Heart Failure Market
12.1. Australia Medications For Heart Failure Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Medications For Heart Failure Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Medications For Heart Failure Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Medications For Heart Failure Market
13.1. Indonesia Medications For Heart Failure Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Medications For Heart Failure Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Medications For Heart Failure Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Medications For Heart Failure Market
14.1. South Korea Medications For Heart Failure Market Overview
14.2. South Korea Medications For Heart Failure Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Medications For Heart Failure Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Medications For Heart Failure Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Medications For Heart Failure Market
15.1. Western Europe Medications For Heart Failure Market Overview
15.2. Western Europe Medications For Heart Failure Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Medications For Heart Failure Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Medications For Heart Failure Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Medications For Heart Failure Market
16.1. UK Medications For Heart Failure Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Medications For Heart Failure Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Medications For Heart Failure Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Germany Medications For Heart Failure Market
17.1. Germany Medications For Heart Failure Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Medications For Heart Failure Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Medications For Heart Failure Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Medications For Heart Failure Market
18.1. France Medications For Heart Failure Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Medications For Heart Failure Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Medications For Heart Failure Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy Medications For Heart Failure Market
19.1. Italy Medications For Heart Failure Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Medications For Heart Failure Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Medications For Heart Failure Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain Medications For Heart Failure Market
20.1. Spain Medications For Heart Failure Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Medications For Heart Failure Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Medications For Heart Failure Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Medications For Heart Failure Market
21.1. Eastern Europe Medications For Heart Failure Market Overview
21.2. Eastern Europe Medications For Heart Failure Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Medications For Heart Failure Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Medications For Heart Failure Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Medications For Heart Failure Market
22.1. Russia Medications For Heart Failure Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Medications For Heart Failure Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Medications For Heart Failure Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Medications For Heart Failure Market
23.1. North America Medications For Heart Failure Market Overview
23.2. North America Medications For Heart Failure Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Medications For Heart Failure Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Medications For Heart Failure Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Medications For Heart Failure Market
24.1. USA Medications For Heart Failure Market Overview
24.2. USA Medications For Heart Failure Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Medications For Heart Failure Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Medications For Heart Failure Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25. Canada Medications For Heart Failure Market
25.1. Canada Medications For Heart Failure Market Overview
25.2. Canada Medications For Heart Failure Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Medications For Heart Failure Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Medications For Heart Failure Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Medications For Heart Failure Market
26.1. South America Medications For Heart Failure Market Overview
26.2. South America Medications For Heart Failure Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Medications For Heart Failure Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Medications For Heart Failure Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Medications For Heart Failure Market
27.1. Brazil Medications For Heart Failure Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Medications For Heart Failure Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Medications For Heart Failure Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Medications For Heart Failure Market
28.1. Middle East Medications For Heart Failure Market Overview
28.2. Middle East Medications For Heart Failure Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Medications For Heart Failure Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Medications For Heart Failure Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Medications For Heart Failure Market
29.1. Africa Medications For Heart Failure Market Overview
29.2. Africa Medications For Heart Failure Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Medications For Heart Failure Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Medications For Heart Failure Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Medications For Heart Failure Market Competitive Landscape And Company Profiles
30.1. Medications For Heart Failure Market Competitive Landscape
30.2. Medications For Heart Failure Market Company Profiles
30.2.1. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
30.2.2. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
30.2.3. Sanofi SA Overview, Products and Services, Strategy and Financial Analysis
30.2.4. Bristol-Myers Squibb Overview, Products and Services, Strategy and Financial Analysis
30.2.5. AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis
31. Medications For Heart Failure Market Other Major And Innovative Companies
31.1. Novartis AG
31.2. Eli Lilly and Company
31.3. Boehringer Ingelheim Pharmaceuticals Inc.
31.4. Steris Pharma
31.5. CSPC Pharmaceutical
31.6. Hikma Pharmaceuticals PLC
31.7. Cadila Pharmaceuticals
31.8. Ionis Pharmaceuticals Inc.
31.9. Valeant Pharmaceuticals International Inc.
31.10. Hainan Poly Pharm. Co. Ltd.
31.11. Addii Biotech
31.12. Lunan Pharmaceutical Group
31.13. Mylan Laboratories Inc.
31.14. Neuracle Lifesciences Private Limited
31.15. JM Laboratories
32. Global Medications For Heart Failure Market Competitive Benchmarking And Dashboard
33. Key Mergers And Acquisitions In The Medications For Heart Failure Market
34. Recent Developments In The Medications For Heart Failure Market
35. Medications For Heart Failure Market High Potential Countries, Segments and Strategies
35.1 Medications For Heart Failure Market In 2029 - Countries Offering Most New Opportunities
35.2 Medications For Heart Failure Market In 2029 - Segments Offering Most New Opportunities
35.3 Medications For Heart Failure Market In 2029 - Growth Strategies
